Steroid Tapering Study for Myasthenia Gravis on Ravulizumab
Treatments studied
Part of Brain & nervous system, Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have generalized myasthenia gravis (gMG).
- You are currently being treated with ravulizumab.
- You have been taking a daily steroid (like prednisone or prednisolone) at a dose of at least 7.5 mg for the past 4 weeks.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
This study looks at protein changes in patients with myasthenia gravis who are taking the medication Ravulizumab. By understanding these changes, researchers hope to learn more about the condition and how the treatment works.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.